<PAGE>

EXHIBIT 99.1

[ADVANCED BOITHERAPY, INC. LOGO]     ADVANCED BIOTHERAPY, INC.
                                     Administration
                                     6355 Topanga Canyon Boulevard, Suite 510
                                     Woodland Hills, California  91367
                                     Laboratories
                                     9110 Red Branch Rd.
                                     Columbia, MD   21045
                                     Telephone 818-883-6716
                                     Fax       818-883-3353
                                     www.advancedbiotherapy.com


                             "FOR IMMEDIATE RELEASE"

     US FOOD AND DRUG ADMINISTRATION GRANTS COMPANY ORPHAN DRUG DESIGNATION

LOS  ANGELES--(BUSINESS  WIRE)--November  24,  2003 - Advanced  Biotherapy  Inc.
(OTCBB:ADVB - News) -- a developer of pioneering antibody therapies for treating
severe and  widespread  autoimmune  diseases - reported today that the Office of
Orphan Products  Development (OPD) of the US Food and Drug Administration  (FDA)
has  granted the  Company  "Orphan  Drug  Designation"  for its  investigational
antibodies to interferon-gamma to treat Immunologic Corneal Allograft Rejection.

Mr. Edmond  Buccellato,  CEO and Chairman of the Board of Directors stated,  "We
are pleased to receive this  notification and  acknowledgement  from the US Food
and Drug  Administration.  Orphan  products are those used to treat  diseases so
rare that they affect  fewer than  200,000  people in the United  States.  Since
therapeutic  biologics  and drugs for rare  diseases and  conditions  often lack
committed  clinical  trial  sponsorship  for  development  and  marketing,  this
designation allows us to take advantage of specific  incentives  provided by the
Orphan  Drug Act (the Act) that  became law in 1983.  We now have  seven  years'
exclusive  license to market the drug upon receiving FDA marketing  approval and
can apply for grants  authorized by the Act to cover the cost of our US clinical
research.  Once an IND  application  has  been  approved  by the  FDA,  clinical
research grants may cover up to $200,000 of direct cost per year for up to three
years.  There is no assurance we will be awarded such grants.  However,  the FDA
has  provided  support  for more than $130  million in orphan  product  research
grants to fund studies on an estimated 180 rare diseases and conditions. The FDA
currently  expends  approximately $12 million annually to fund about 100 studies
in various stages of clinical  evaluation of potential  therapies for these rare
diseases.

As published last year in the "American  Journal of  Ophthalmology"  (June 2002,
vol. 133), our Company sponsored an open label investigational clinical trial in
Moscow,  Russia, at the Central Clinical Research Institute of Eyes, in which we
reported  halting corneal  transplant  rejection in all 13 patients by using our
investigational antibodies as a topical treatment in the form of eye drops.


Page 1 of 2

<PAGE>

EXHIBIT 99.1


Corneal transplantation replaces a patient's diseased cornea with healthy tissue
from an  unrelated  donor.  It is the final  recourse  for  patients  blind from
corneal disease.  However, it is frequently complicated by immunologic rejection
when the immune system of the recipient  recognizes the donor tissue as foreign.
Development of this  investigational drug for corneal transplant rejection could
open the door for  preventing  rejection  of other  transplanted  organs such as
kidney,  heart,  and liver.  The Company has an agreement  with a major clinical
institute of transplantation to begin studies of the use of our antibody therapy
to stop organ transplant rejection."

About Advanced Biotherapy

Advanced Biotherapy,  Inc., located in Los Angeles, with laboratories located in
Columbia,  Maryland, is pioneering the development of new antibody therapies for
treating  severe  and  widespread   autoimmune  diseases.   Its  investigational
therapies  attack  autoimmune  diseases at their source,  neutralizing  biologic
imbalances  that impair immune  system  function.  Core  technology is protected
under U.S.  patents and  patents  pending  for the  exclusive  use of a class of
antibodies  to the protein  known as  interferon-gamma  and  antibodies to other
proteins  for  treating  a  range  of  autoimmune  diseases.   The  company  has
experienced very encouraging  results treating  multiple  sclerosis,  rheumatoid
arthritis,  and certain autoimmune skin conditions,  including psoriasis,  using
its investigational anti-interferon-gamma.

Statements made in this news release,  other than statements of historical fact,
are forward-looking statements and are subject to a number of uncertainties that
could cause actual results to differ materially from the anticipated  results or
other expectations  expressed in our forward-looking  statements.  Some of these
forward-looking  statements  may be  identified  by  the  use  of  words  in the
statements such as  "anticipate,"  "estimate,"  "expect,"  "project,"  "intend,"
"plan,"  "believe"  or other words and terms of similar  meaning.  The risks and
uncertainties  which may affect the  development,  operations and results of our
business  include,  but are not limited to the following:  risks associated with
clinical trials, the uncertainties of research and product development programs,
the uncertainties of the regulatory  approval process,  the risks of competitive
products,  the risks of our current capital  resources,  the uncertainties as to
the availability of future capital and our future capital requirements,  and the
risks associated with the extent and breadth of the Company's patent  portfolio.
The foregoing  discussion of the pending clinical  investigations and the effect
of the patents issued and pending  involves risks and  uncertainties,  including
but not limited to the risks that third parties may be successful in challenging
such  patents;  or that  granted  claims  may be  held  invalid  or  interpreted
differently by a court of law; or that new  technologies  will be developed that
are  superior in treating  the diseases  targeted by Advanced  Biotherapy,  Inc.
Readers are cautioned not to place reliance on these forward-looking statements,
which  speak only as of the date the  statements  were made.  See the  Company's
public  filings  with  the  Securities  and  Exchange   Commission  for  further
information  about risks and  uncertainties  that may affect the Company and the
results or expectations expressed in our forward-looking  statements,  including
the section  captioned  "Factors  That May Affect The Company"  contained in the
Company's  Annual Report on Form 10-KSB/A for the fiscal year ended December 31,
2002.


--------------------

Contact:
     Advanced Biotherapy, Inc.
     Amy Buccellato, 818-883-6716
     www.advancedbiotherapy.com


Page 2 of 2

